我們已在上線！進一步了解

Biodesix

BDSX

市值 US$2.5億

23.66 USD

-1.05

4.25%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

23.66

0.00

0%

1天

-4.25%

5天

-9.07%

1個月

-17.16%

3個月

18.54%

6個月

77.76%

今年迄今

266.25%

1年

240.43%

5年

-83.55%

10年

-90.77%

關於： Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

員工： 334

醫療保健診斷與研究

新聞

正面

中性

負面

市場情緒 3個月

正面 47.4%

中性 52.6%

負面 0%

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

Zacks Investment Research

Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests

BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.

Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Biodesix: Growing Fast While Trading Below Many Diagnostics Peers

Biodesix is gaining momentum in lung diagnostics, with >30% revenue growth and accelerating test volumes. BDSX boasts 80%+ gross margins and improving operating leverage, supporting a credible path to profitability despite ongoing cash burn. The stock trades at a discounted EV/Sales multiple versus peers, despite industry-leading gross margins and robust clinical evidence.

Biodesix: Growing Fast While Trading Below Many Diagnostics Peers

Biodesix to Participate in Upcoming Investor Conferences

LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences:

Biodesix to Participate in Upcoming Investor Conferences

Zacks Investment Research

What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?

Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?

Zacks Investment Research

Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?

The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?

Zacks Investment Research

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference

Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the principal drivers of its growth strategy.

Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference

查看新聞排名

價格圖表採用Lightweight Charts™實作